Data compiled by Redley Lamar · ChainSifter Intelligence
7Suppliers
11Customers
2Debt Items
20Related Chains
Source-Backed Evidence Depth
BioMarin Pharmaceutical Inc. (BMRN) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
21Total relationships
2Distinct source URLs
8High confidence
0.771Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Reciprocal relationship from CAMP graph: ty fee qualifies for the royalty constraint exception and does not require an estimate of the future transaction price. The Company did not record any license…
FOLD
Amicus Therapeutics Inc
72%
Reciprocal relationship from FOLD graph: ange or other circumstance that could give rise to the termination of the definitive merger agreement (the "Merger Agreement") that we entered into with BioMa…
Reciprocal relationship from LLY graph: 8,190.0 $ 14,667.5 $ 12,333.1 $ 10,351.3 Numbers may not add due to rounding. (1) Jardiance revenue includes Glyxambi, Synjardy, and Trijardy XR. (2) Humalog r…
Reciprocal relationship from PHVS graph: ion), after deducting $0.3 million (€0.3 million), which was payable to Leerink Partners, LLC as commission in respect of such sales. The Company has not sold…
Reciprocal relationship from SPRB graph: suance of the Avenue Warrant on March 9, 2026, the shares into which the Avenue Warrant will be issued became fixed and therefore the Company reassessed its a…
Reciprocal relationship from SRPT graph: past several years to further enhance our internal research and development capabilities. However, we currently do not have internal GMP manufacturing capabil…
Reciprocal relationship from TRDA graph: f treatment with our therapeutics in relation to alternative treatments and therapies; • our ability to obtain and maintain sufficient third-party coverage an…
BioMarin Pharmaceutical Inc. Customers
Ticker
Name
Confidence
Evidence
AMICUS-THERAPEUTICS-INC
AMICUS-THERAPEUTICS-INC
92%
Under the Merger Agreement, receipt of the French FDI Clearance satisfies the final condition to the Merger other than conditions that by their nature are to be satisfied at the closing of the Merger.
SANOFI
SANOFI
92%
As of March 31, 2026, and December 31, 2025, the accounts receivable balance for Sanofi included $ 152.6 million and $ 148.0 million, respectively, of unbilled accounts receivable, which becomes paya…
Reciprocal relationship from SPRB graph: Reciprocal relationship from BMRN graph: Reciprocal relationship from SPRB graph: mmercial sale. In addition, we will also be entitled to receive a royalty fo…
INOZYME-PHARMA-INC
INOZYME-PHARMA-INC
85%
ternal innovation. In April 2026, we acquired Amicus Therapeutics, Inc. (Amicus) to expand and diversify our rare disease product portfolio (the Amicus Acquisition). In addition, in July 2025 we acqu…
SNYNF
Sanofi
72%
and timing of orders in countries that place large government orders; and • VOXZOGO: higher sales volume from new patients initiating therapy across all regions. These increases were partially offset…
SNYNF
Sanofi
72%
Reciprocal relationship from SNYNF graph: Reciprocal relationship from BMRN graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from BMRN graph: and timing of orders in countries…
Reciprocal relationship from SRPT graph: Reciprocal relationship from BMRN graph: Reciprocal relationship from SRPT graph: Reciprocal relationship from BMRN graph: Reciprocal relationship from SRPT g…
Reciprocal relationship from TRDA graph: Reciprocal relationship from BMRN graph: Reciprocal relationship from TRDA graph: Reciprocal relationship from BMRN graph: Reciprocal relationship from TRDA g…
BIOMARIN-GENZYME-LLC
BIOMARIN-GENZYME-LLC
62%
ufacturing facilities to manufacture our finished products and product candidates. Numerous factors could cause interruptions in the supply or manufacture of our products and product candidates, incl…
CAPITAL-RESOURCES
CAPITAL-RESOURCES
62%
historically collected receivables from customers in such countries, sustained weakness or further deterioration of the local economies and currencies may cause customers in those countries to be una…
Reciprocal relationship from CRS graph: Reciprocal relationship from BMRN graph: historically collected receivables from customers in such countries, sustained weakness or further deterioration of th…
BioMarin Pharmaceutical Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
BMRN-DEBT
Debt stack $4.2B
90%
Market cache reports total debt of $4.2B.
BMRN-DEBT-8287
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2022-12-31.
BioMarin Pharmaceutical Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for BioMarin Pharmaceutical Inc..
BioMarin Pharmaceutical Inc. Ownership
Holder
Name
Confidence
Evidence
BMRN-OWNER-BARCLAYS-PLC
BARCLAYS PLC
90%
13F overlay lists BARCLAYS PLC as top holder; 560 tracked holders.
BioMarin Pharmaceutical Inc. Extended Supply Chain Network
